ASH 2023 | Impact of recent advancements in treatment of R/R AML on OS in clinical practice

Keri Maher, DO, VCU Health, Richmond, VA, summarizes data coming from a retrospective study looking at the impact of recent advancements in therapies for relapsed/refractory acute myeloid leukemia (R/R AML) on overall survival (OS). A cohort of 257 adult patients with R/R AML, treated at the VCU Massey Comprehensive Cancer Center, were retrospectively studied from 2015–2019 (this cut-off was used in order to exclude data following the COVID-19 pandemic, as this was a compounding factor). The data showed that the prognosis for patients in this group remains poor, despite the advances made, although some modest improvements in survival have been achieved, largely for patients with the ELN 2022 favorable-risk disease. This study highlights the need for improved therapeutics aimed at those with R/R disease. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.